OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Hematology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Iron biology: the balance matters	59
outside front cover, PMS 8883 metallic AND 4/C	52
Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023	49
Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?	43
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients	42
Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach	39
Forging international collaboration and alliances to establish the largest transplant center in the north of Vietnam	36
CAR T-cell therapy comes of age: Introductory editorial for the special issue	34
Clinical applications of circulating tumor DNA in Hodgkin lymphoma	33
Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia	33
Epidemiology of VITT	33
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy	27
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana	26
Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes	25
Therapy-related myelodysplastic syndromes and acute myeloid leukemia	24
Laboratory testing for VITT antibodies	23
Clonal hematopoiesis in the setting of hematopoietic cell transplantation	21
Cell senescence and malignant transformation in the inherited bone marrow failure syndromes: Overlapping pathophysiology with therapeutic implications	20
Looking to achieve cure the first time around for DLBCL patients who are older and/or with co-morbidities	14
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation	14
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial	14
Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin	13
outside front cover, PMS 8883 metallic AND 4/C	13
License for a CAR T: Examining patient eligibility	12
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa	12

The role of response adapted therapy in the era of novel agents	11
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients	11
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors	10
Palliative care needs of patients with hematologic malignancies and family caregivers and challenges of palliative care provision in Asia: A review of evidence	9
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies	9
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria	9
Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress	9
outside front cover, PMS 8883 metallic AND 4/C	8
The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT)	8
Advances in understanding the crosstalk between mother and fetus on iron utilization	8
Germline predisposition for clonal hematopoiesis	8
Platelet-activating anti-PF4 disorders: An overview	7
Shaping the bone through iron and iron-related proteins	7
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care	7
The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era	7
outside front cover, PMS 8883 metallic AND 4/C	6
Collaborations, colleagues, and friendships: The Hematology Branch and blood disease centers in Asia	6
How to set up a clinical research center in Brazil, as an example of a middle-income country	6
Metabolic reprogramming in the CLL TME; potential for new therapeutic targets	6
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management	6
Updates on the biology of chronic lymphocytic leukemia: introductory editorial	6
RNA splicing as a therapeutic target in myelodysplastic syndromes	5
Cell-free DNA in large B-cell lymphoma: MRD and beyond	5
Mouse models of CLL: In vivo modeling of disease initiation, progression, and transformation	5
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19	5
CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?	5
Smoldering multiple myeloma: Integrating biology and risk into management	5
Management of Angioimmunoblastic T-Cell Lymphoma (AITL) and other T Follicular Helper Cell lymphomas (TFH PTCL)	5
Inflammation in myelodysplastic syndrome pathogenesis	5
Somatic mutations and clonal expansions in paroxysmal nocturnal hemoglobinuria	5
The role of viruses in HIV-associated lymphomas	4
SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies	4
Aplastic anemia: Pathophysiology	4
outside front cover, PMS 8883 metallic AND 4/C	4
FaMMily Affairs: Dissecting inherited contributions to multiple myeloma risk	4
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS	4
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence	4
Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas	4
Epidemiology and etiology of diffuse large B-cell lymphoma	4
Somatic mutations in “benign” blood diseases	4
Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome	4
TET2 mutation as prototypic clonal hematopoiesis lesion	4
Clonal dynamics of hematopoietic stem cell compartment in aplastic anemia	4
Beyond HMAs: Novel Targets and Therapeutic Approaches	4
Iron metabolism in infections: Focus on COVID-19	4
outside front cover, PMS 8883 metallic AND 4/C	4
Novel therapies targeting cutaneous T cell lymphomas and their microenvironment	3
Tuning CAR T-cell therapies for efficacy and reduced toxicity	3
Genetics of somatic auto-inflammatory disorders	3
Lessons learned from the Eµ-TCL1 mouse model of CLL	3

Special edition of the Seminars in Hematology series on Global Hematology Care	3
The pediatric approach to Hodgkin lymphoma	3
Antibody and immunotherapy in diffuse large B-cell lymphoma	3
A line in shifting sand: Can we define and target TP53 mutated MDS?	3
Beyond SARS-CoV2, the role of viruses in the pathogenesis of hematologic malignancies	3
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services	3
Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma	3
A Call to Arms: Overcoming challenges in Myelodysplastic Syndromes therapy advances	3
Cellular therapies: Hematology and beyond	2
Primary and secondary central nervous system mature T- and NK-cell lymphomas	2
The case for prioritizing malignant hematology services in low- and middle-income countries	2
Toward a pathophysiology inspired treatment of VEXAS syndrome	2
Prognosis and risk stratification of peripheral T-cell lymphomas	2
Diagnosis and management of adult T-cell leukemia/lymphoma	2
Clonal hematopoiesis and autoimmunity	2
Role of the tumor microenvironment in CLL pathogenesis	2
Contemporary radiation therapy use in Hodgkin lymphoma	2
Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma	2
Immunocompetent mouse models of multiple myeloma	2
VEXAS within the spectrum of rheumatologic disease	2
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics	1
outside front cover, PMS 8883 metallic AND 4/C	1
Clinical applications of circulating tumor DNA in central nervous system lymphoma	1
outside front cover, PMS 8883 metallic AND 4/C	1
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future	1
Implications for metabolic disturbances in myelodysplastic syndromes	1
Somatic mutations in VEXAS Syndrome and Erdheim-Chester disease: Inflammatory myeloid diseases	1
Evidence-based management of primary and secondary CNS lymphoma	1
Clonal hematopoiesis in children with predisposing conditions	1
The epidemiology of Waldenström macroglobulinemia	1
Introduction to series: Diffuse large B-cell lymphoma	1
outside front cover, PMS 8883 metallic AND 4/C	1
outside front cover, PMS 8883 metallic AND 4/C	1
Mechanisms of cellular iron sensing, regulation of erythropoiesis and mitochondrial iron utilization	1
Iron and erythropoiesis: A mutual alliance	1
Circulating tumor DNA in NK/T and peripheral T cell lymphoma	1
Vaccinations in patients with chronic lymphocytic leukemia	1
Clinical manifestations of clonal hematopoiesis: What has SF3B1-mutant MDS taught us?	1
outside front cover, PMS 8883 metallic AND 4/C	1
The molecular map of CLL and Richter's syndrome	1
Applications of virus-specific T cell therapies post-BMT	1
T-cell lymphomas: A 5-body problem	1
outside front cover, PMS 8883 metallic AND 4/C	1
Special issue on circulating tumor DNA: Introductory editorial	1
Somatic mutations in acquired pure red cell aplasia	1
Understanding MDS stem cells: Advances and limitations	1
Somatic compensation of inherited bone marrow failure	1
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma?	1
The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL	1
outside front cover, PMS 8883 metallic AND 4/C	1
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?	1
Place of care manufacturing of chimeric antigen receptor cells: Opportunities and challenges	1